Acrux Of Australia Eyes Big Win In U.S. Approval For Testosterone Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Acrux could see $1 billion in sales next year for its Axiron (testosterone) supplement delivered as an underarm spray